Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials by Jacob, Matthias et al.
Open Access
Available online http://ccforum.com/content/12/2/R34
Page 1 of 13
(page number not for citation purposes)
Vol 12 No 2 Research
Small-volume resuscitation with hyperoncotic albumin: a 
systematic review of randomized clinical trials
Matthias Jacob1, Daniel Chappell1, Peter Conzen1, Mahlon M Wilkes2, Bernhard F Becker3 and 
Markus Rehm1
1Klinik für Anästhesiologie, Ludwig-Maximilians-Universität, Klinikum Grosshadern, Nussbaumstrasse 20, D-80336 Munich, Germany
2Hygeia Associates, 17988 Brewer Road, Grass Valley, California 95949, USA
3Physiologisches Institut – Vegetative Physiologie, Ludwig-Maximilians-Universität, Schillerstrasse 44, D-80336 Munich, Germany
Corresponding author: Matthias Jacob, matthias.jacob@med.uni-muenchen.de
Received: 30 Oct 2007 Revisions requested: 11 Dec 2007 Revisions received: 16 Feb 2008 Accepted: 4 Mar 2008 Published: 4 Mar 2008
Critical Care 2008, 12:R34 (doi:10.1186/cc6812)
This article is online at: http://ccforum.com/content/12/2/R34
© 2008 Jacob et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background Small-volume resuscitation can rapidly correct
hypovolemia. Hyperoncotic albumin solutions, long in clinical
use, are suitable for small-volume resuscitation; however, their
clinical benefits remain uncertain.
Methods Randomized clinical trials comparing hyperoncotic
albumin with a control regimen for volume expansion were
sought by multiple methods, including computer searches of
bibliographic databases, perusal of reference lists, and manual
searching. Major findings were qualitatively summarized. In
addition, a quantitative meta-analysis was performed on
available survival data.
Results In all, 25 randomized clinical trials with a total of 1,485
patients were included. In surgery, hyperoncotic albumin
preserved renal function and reduced intestinal edema
compared with control fluids. In trauma and sepsis, cardiac
index and oxygenation were higher after administration of
hydroxyethyl starch than hyperoncotic albumin. Improved
treatment response and renal function, shorter hospital stay and
lower costs of care were reported in patients with liver disease
receiving hyperoncotic albumin. Edema and morbidity were
decreased in high-risk neonates after hyperoncotic albumin
administration. Disability was reduced by therapy with
hyperoncotic albumin in brain injury. There was no evidence of
deleterious effects attributable to hyperoncotic albumin. Survival
was unaffected by hyperoncotic albumin (pooled relative risk,
0.95; 95% confidence interval 0.78 to 1.17).
Conclusion In some clinical indications, randomized trial
evidence has suggested certain benefits of hyperoncotic
albumin such as reductions in morbidity, renal impairment and
edema. However, further clinical trials are needed, particularly in
surgery, trauma and sepsis.
Introduction
The advantages of small-volume resuscitation in rapidly cor-
recting hypovolemia and interrupting the pathological proc-
esses leading to multi-organ failure and other poor outcomes
are well recognized [1]. The use of hyperosmolar solutions
containing artificial colloid for small-volume resuscitation has
been described previously [2]. Another fluid type suitable for
small-volume resuscitation is hyperoncotic (20 to 25%) albu-
min. Indeed, the original form of albumin developed in the early
1940s for resuscitation of combat casualties was a hyperon-
cotic 25% solution, designed for portability [3]. Currently, 4 to
5% albumin solutions are also widely employed for volume
expansion. Whereas 4 to 5% albumin expands intravascular
volume by approximately 80% of the administered volume [4-
15], the corresponding effect of 20% albumin averages 210%
[4,16-18] and 25% albumin 260% [4,19-21]. Consequently,
hyperoncotic albumin can accomplish the same volume expan-
sion effect as 4 to 5% albumin using only roughly one-third of
ANP = atrial natriuretic peptide; APACHE = Acute Physiology and Chronic Health Evaluation; apt = activated partial thromboplastin time; CI = con-
fidence interval; COP = colloid oncotic pressure; CVP = central venous pressure; DO2I = oxygen delivery index; HES = hydroxyethyl starch; IQR = 
interquartile range; ISS = injury severity score; MAP = mean arterial pressure; PaO2/FiO2 = ratio of partial pressure of arterial oxygen to fraction of 
inspired oxygen; PCWP = pulmonary capillary wedge pressure; pHi = gastric intramucosal pH; PT = prothrombin time; RL = Ringer's lactate; RR = 
relative risk; RVEF = right ventricular ejection fraction; sELAM-1 = soluble endothelial leucocyte adhesion molecule-1; sICAM-1 = soluble intercellular 
adhesion molecule-1; SVRI = systemic vascular resistance index; VO2I = oxygen consumption index.Critical Care    Vol 12 No 2    Jacob et al.
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the administered volume, thus diminishing the time needed to
attain the desired expansion of the intravascular space. The
disproportion in administered volume is far greater vs crystal-
loid, since, for example, the required volume of Ringer's lactate
(RL) was fourfold that of 5% albumin to achieve the same
hemodynamic endpoints in a randomized trial of patients with
multiple trauma and shock [22]. Furthermore, the effect of
hyperoncotic albumin is relatively long lasting, with at least
two-thirds of the initial volume expansion effect persisting at
6–8 h after infusion [19,21].
Hyperoncotic albumin also possesses the capacity to draw
interstitial fluid into the intravascular space, in accord with the
Starling fluid equilibrium equation [23]. Thus, undesirable
edema may be reduced [24].
Nonetheless, it has remained unclear whether the properties
of hyperoncotic albumin can translate into demonstrable clini-
cal benefits. The only large-scale randomized trial of outcomes
after albumin administration, the Saline versus Albumin Fluid
Evaluation (SAFE) trial [25], compared 4% albumin with nor-
mal saline for management of hypovolemia, and no difference
in survival was detected. Systematic reviews of mortality, mor-
bidity and other endpoints thus far have not discriminated
between 4 to 5% and 20 to 25% solutions of albumin [26-30].
The multi-center non-randomized observational Sepsis Occur-
rence in Acutely ill Patients (SOAP) study also did not differ-
entiate between types of albumin solutions [31].
The present systematic review of randomized clinical trials is
focused exclusively on hyperoncotic albumin solutions. A qual-
itative critical appraisal of the randomized trial evidence is pre-
sented. Additionally, a quantitative meta-analysis of survival
after hyperoncotic albumin administration is reported.
Methods
Objectives
This systematic review of randomized clinical trials was under-
taken to determine whether hyperoncotic albumin consistently
differs from control regimens in its effects upon clinically rele-
vant endpoints such as morbidity, major organ function, length
of stay and cost of care in acutely ill patients. Such endpoints
are often not defined, assessed and reported in a consistent
and standardized manner, so qualitative summarization is more
appropriate than quantitative combination of results across tri-
als. A secondary objective was to evaluate the effect of hyper-
oncotic albumin on survival by quantitative meta-analysis.
Inclusion criteria
All randomized clinical trials comparing hyperoncotic albumin
with a control regimen for volume expansion in acutely ill
patients were eligible for inclusion. Both parallel-group and
crossover study designs were acceptable. Randomized trials
focusing on other uses of albumin such as treatment of hyper-
bilirubinemia, extracorporeal albumin dialysis or prevention of
ovarian hyperstimulation syndrome were excluded. Also
excluded were randomized trials of albumin as an adjunct to
paracentesis or for correction of hypoalbuminemia, both of
which have been evaluated in previous systematic reviews
[28,29].
Identification of studies
Randomized clinical trials fulfilling the inclusion criteria for the
systematic review were identified by multiple methods, includ-
ing computer searches of the Medline and EMBASE biblio-
graphic databases and the Cochrane Library. Search terms
included hyperoncotic albumin, resuscitation, hypovolemia,
surgery, trauma, sepsis, liver diseases, intensive care, neona-
tal, brain injuries, nephrotic syndrome and randomized control-
led trials. Studies were also sought through examination of
reference lists and manual searching of Index Medicus and
specialty journals. No restrictions on time period or language
of publication were applied.
Data extraction
Data on numbers of patients randomized, clinical indication,
hyperoncotic albumin and control regimen, major findings and
deaths were extracted from the randomized clinical trial
reports and used to populate a relational database. The partic-
ipating investigators, time periods and study subject charac-
teristics were closely examined to avoid inclusion of duplicate
datasets appearing in multiple publications and to ensure the
most complete possible dataset. Deaths were recorded on an
intent-to-treat basis. Unpublished survival data and clarifica-
tion regarding study design features were sought as needed
via direct inquiries with the randomized trial investigators.
Quality assessment
Trial quality was evaluated by the criteria of blinding and allo-
cation concealment. On the basis of the procedures employed
in the study, allocation concealment was classified as ade-
quate, inadequate or unclear [32].
Statistical analysis
R version 2.4.1 (The R Foundation for Statistical Computing,
Vienna, Austria), Stata 9.1 (Stata Corp., College Station, TX,
USA) and SPSS 11.5 (SPSS Inc., Chicago, IL, USA) statisti-
cal software was used for analyses. The attributes of the
included trials were summarized by descriptive statistics, i.e.,
the median and interquartile range (IQR).
The primary endpoint for the quantitative meta-analysis of sur-
vival was the relative risk (RR) of death. The 95% confidence
interval (CI) of RR was also calculated. RR can only be calcu-
lated when at least one death has been observed; hence, trials
with no deaths did not enter the survival meta-analysis. Deaths
in crossover trials were also excluded from the meta-analysis,
since in such trials the same patients are exposed to both the
albumin and control regimens and the attributability of death to
one regimen or the other is uncertain. Pooled RR wasAvailable online http://ccforum.com/content/12/2/R34
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estimated under a fixed-effects model. Publication bias was
assessed by the method of Egger et al. [34]. The statistical
power of the meta-analysis was calculated as 1 - Φ (Cα/2 - λ)
+ Φ (-Cα/2 - λ), where Φ = the standard normal cumulative dis-
tribution function, Cα/2 = the standard normal critical value for
a two-sided test at the 0.05 α level, and λ = (ln(pooled RR) -
1)/(pooled standard error) [34].
Results
Included trials
A total of 25 randomized clinical trials [35-59] with an aggre-
gate of 1,485 patients were included in the review (Figure 1).
The median number of patients per trial was 30 (IQR, 18–58).
In all, 21 of the trials (84%) had been published from 1990
onwards. Parallel groups were compared in 21 trials, and a
crossover design was employed in the remaining 4. The con-
trol regimen consisted of another colloid, predominantly
hydroxyethyl starch (HES), in nine trials (36%), crystalloid in
four (16%), no albumin in six (24%) and lower-dose albumin in
one (4%). Two separate control regimens composed of
another colloid and either crystalloid or no albumin were
administered in five trials (20%).
In five trials, the effects of hyperoncotic albumin were sepa-
rately investigated among patients with either trauma or sepsis
[44-46,48,49]. Randomized comparisons involving surgery
and trauma are summarized in Table 1, sepsis in Table 2 and
other indications in Table 3. The other indications were com-
prised of liver disease, high-risk neonates, brain injury, intradi-
alytic hypotension and nephrotic syndrome. The trials of high-
risk neonates involved premature infants with risk factors such
as low birth weight, respiratory dysfunction or brain injury.
Evaluated study endpoints included survival in three trials
[40,51,53], morbidity in six [35,40,43,53,56,58], major organ
function in six [41,42,49,56,58,5 9 ] ,  l e n g t h  o f  s t a y  i n  t w o
[51,56], and costs of care in one [51]. Among additional end-
points assessed were hemodynamics in seven trials
[45,48,49,52,54,55,59], major organ edema in two [39,56],
whole body edema in two [38,42], coagulation function in four
[39,44,46,49], colloid oncotic pressure (COP) in two [36,37],
diuretic responsiveness in two [50,57], and inflammatory
markers in one [47].
Trial quality
Four trials (16%) were blinded [41,50,53,56], and the remain-
der unblinded. Allocation concealment was adequate in four
trials (16%) [50,51,53,58] and inadequate or unclear in the
rest.
Surgery
Based on randomized clinical trial data from surgical patients
summarized in Table 1, hyperoncotic albumin more effectively
maintained colloid oncotic pressure than control regimens in
both cardiac [37] and non-cardiac surgery [36]. Compared
with HES, hyperoncotic albumin better preserved renal func-
tion [41] and coagulation [39]. A greater increase in cardiac
output was demonstrated after administration of hyperoncotic
albumin than saline to the same right atrial pressure target
[52]. Hyperoncotic albumin was superior to both HES and
crystalloid in preventing intestinal edema during abdominal
surgery [39].
Figure 1
Selection process for randomized clinical trials Selection process for randomized clinical trials.Critical Care    Vol 12 No 2    Jacob et al.
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Trauma
In contrast, among the five randomized comparisons in trauma
described by Boldt et al. (Table 1) no apparent clinical advan-
tages of hyperoncotic albumin over HES were apparent in
three reports [44,46,48]. In the other two reports [45,49], car-
diac index and oxygenation were increased by HES relative to
albumin.
Sepsis
Similarly, in sepsis (Table 2) higher cardiac index and oxygen-
ation after HES than albumin administration were observed in
several trials [45,49,59]. Additionally, HES maintained higher
gastric intramucosal pH than hyperoncotic albumin in two tri-
als [45,48] and improved Acute Physiology and Chronic
Health Evaluation II score in one [59].
Liver disease
In cirrhotic patients with refractory ascites (Table 3), hyperon-
cotic albumin increased the treatment response rate, short-
ened hospital stay and reduced costs of care [51]. In patients
Table 1
Randomized clinical trials of hyperoncotic albumin in surgery and trauma
Trial n Indication Regimen Results
Cardiac surgery
Boldt et al., 1986 [37] 55 Coronary artery bypass 
grafting
300 ml 20% albumin intraoperatively 
after bypass vs 500 ml 3% HES 200/
0.5 vs 500 ml 3.5% gelatin vs no 
additional volume
Post-bypass COP rebound greater in 
albumin than other groups (p < 0.05)
Boldt et al., 1993 [41] 30 Cardiac defect repair in 
children < 3 years old
20% albumin vs 6% HES 200/0.5 to 
stabilize hemodynamics before bypass
On-bypass urine output in HES group 
lower by 57% than that of albumin 
group (p < 0.05)
Magder and Lagonidis, 
1999 [52]
28 Stable patients after 
cardiac bypass surgery
100 ml 25% albumin vs saline to 
increase right atrial pressure by 2 mm 
Hg
Greater increase in cardiac output 
among hyperoncotic albumin 
recipients, suggesting an inotropic 
effect
Non-cardiac surgery
Zetterström and 
Hedstrand, 1981 [36]
30 Elective major abdominal 
surgery
300–400 ml 20% albumin on 
operation day, 200 ml on next day and 
100 ml/day for subsequent 3 days vs 
no albumin
In albumin recipients COP significantly 
closer to preoperative level on 
postoperative days 2–6
Prien et al., 1990 [39] 18 Abdominal surgery 20% albumin vs 10% HES 200/0.5 vs 
Ringer's lactate to maintain 
preoperative CVP
Significantly lower intraoperative 
intestinal edema after albumin 
compared with either HES or Ringer's 
lactate; impaired coagulation in HES 
recipients
Trauma
Boldt et al., 1995 [44] 30 Trauma of ISS > 15 20% albumin vs 10% HES 200/0.5 to 
12–16 mm Hg target CVP, PCWP or 
both
No between-group differences in daily 
profiles of plasma thrombomodulin, 
proteins C and S and thrombin-
antithrombin III
Boldt et al., 1996 [45] 30 Trauma of ISS between 15 
and 30
20% albumin vs 10% HES 200/0.5 to 
12–18 mm Hg target PCWP
HES 200/0.5 but not albumin 
increased cardiac index, PaO2/FiO2, 
DO2I and VO2I (p < 0.05 for all 
comparisons)
Boldt et al., 1996 [46] 28 Trauma of ISS > 15 20% albumin vs 10% HES 200/0.5 to 
12–16 mm Hg target CVP, PCWP or 
both
Maximum platelet aggregation 
declined in both groups (p < 0.05)
Boldt et al., 1996 [48] 28 Trauma of ISS > 15 20% albumin vs 10% HES 200/0.5 to 
10–15 mm Hg target PCWP
Vasopressin decreased in HES 200/
0.5 but not albumin group (p < 0.05)
Boldt et al., 1998 [49] 150 Trauma of ISS > 15 20% albumin vs 10% HES 200/0.5 to 
12–15 mm Hg target PCWP
PaO2/FiO2 increased by HES 200/0.5 
but not albumin (p < 0.05); higher 
cardiac index, DO2I and VO2I in HES 
200/0.5 group (p < 0.05 for all 
comparisons); no differences in 
incidence of renal failure, platelet 
count, PT or aPTT
aPTT, activated partial thromboplastin time; COP, colloid oncotic pressure; CVP, central venous pressure; DO2I, oxygen delivery index; HES, 
hydroxyethyl starch; ISS, injury severity score; PaO2/FiO2, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; PCWP, 
pulmonary capillary wedge pressure; PT, prothrombin time; VO2I, oxygen consumption index.Available online http://ccforum.com/content/12/2/R34
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developing spontaneous bacterial peritonitis, hyperoncotic
albumin diminished the incidence of renal impairment [53].
Unlike HES 200/0.5 (molecular weight/molar substitution
ratio), hyperoncotic albumin improved circulatory function of
patients with spontaneous bacterial peritonitis [58].
High-risk neonates
In randomized trials of high-risk premature infants (Table 3),
hyperoncotic albumin reduced the frequency of illnesses, less-
ened whole body edema and improved respiratory function
[35,42]. Apgar scores were higher, the frequency of cerebral
edema lower and hospital stay shorter after hyperoncotic albu-
min administration in newborns with asphyxia and brain edema
[56].
Brain injury
Hyperoncotic albumin reduced disability at 3 months in
patients with acute ischemic stroke and normal hematocrit
(Table 3) [40]. Use of hyperoncotic albumin to maintain high
oncotic pressure also led to more favorable outcomes in a ran-
domized trial of patients with closed head injury [43]. All
patients receiving high-oncotic-pressure therapy recovered
with minimal or no neurological deficit, whereas 30% of the
control group remained in a vegetative state or died.
Intradialytic hypotension
In two randomized crossover trials (Table 3), hyperoncotic
albumin was more effective than either saline [54] or hyper-
tonic saline [55] in averting blood volume declines. Systolic
hypotension was also reduced by hyperoncotic albumin com-
pared with saline [55].
Table 2
Randomized clinical trials of hyperoncotic albumin in sepsis
Trial n Indication Regimen Results
Boldt et al., 1995 [44] 30 Sepsis after major surgery 20% albumin vs 10% HES 
200/0.5 to 12–16 mm Hg 
target CVP, PCWP or both
Plasma thrombomodulin increased in albumin 
group and remained unchanged in HES 200/0.5 
group (p < 0.05); plasma protein C among HES 
200/0.5 recipients increased on days 4 and 5 
without corresponding change in albumin group (p 
< 0.05)
Boldt et al., 1996 [45] 30 Sepsis secondary to major 
general surgery
20% albumin vs 10% HES 
200/0.5 to 12–18 mm Hg 
target PCWP
HES 200/0.5 but not albumin increased cardiac 
index, RVEF, PaO2/FiO2, DO2I and VO2I and 
decreased SVRI (p < 0.05 for all comparisons); 
pHi decreased in albumin but not HES 200/0.5 
group (p < 0.05)
Boldt et al., 1996 [46] 28 Sepsis after major surgery 20% albumin vs 10% HES 
200/0.5 to 12–16 mm Hg 
target CVP, PCWP or both
Maximum platelet aggregation declined in both 
groups (p < 0.05)
Boldt et al., 1996 [47] 42 Sepsis secondary to major 
surgery
20% albumin vs 6% HES 
200/0.5 vs pentoxyfylline 
(300 mg bolus plus 1.4 
mg/kg/h continuous 
infusion)
Circulating sELAM-1 and sICAM-1 concentrations 
reduced by HES 200/0.5 compared with albumin 
(p < 0.05 for both comparisons)
Boldt et al., 1996 [48] 28 Sepsis secondary to major 
surgery
20% albumin vs 10% HES 
200/0.5 to 10–15 mm Hg 
target PCWP
Vasopressin, endothelin-1, norepinephrine and 6-
keto-prostaglandin F1a decreased and pHi 
increased in HES 200/0.5 but not albumin group 
(p < 0.05 for all comparisons); ANP increased by 
albumin but not HES 200/0.5 (p < 0.05)
Boldt et al., 1998 [49] 150 Postoperative sepsis 20% albumin vs 10% HES 
200/0.5 to 12–15 mm Hg 
target PCWP
PaO2/FiO2 increased and lactate decreased by 
HES 200/0.5 but not albumin (p < 0.05 for both 
comparisons); higher cardiac index, DO2I and 
VO2I in HES 200/0.5 group (p < 0.05 for all 
comparisons); no differences in incidence of renal 
failure, platelet count, PT or aPTT
Palumbo et al., 2006 [59] 20 Severe sepsis 20% albumin vs 6% HES 
130/0.4
PCWP of 15–18 mm Hg successfully maintained 
by both colloids throughout the 5-day study 
period; temperature, MAP, pulmonary artery 
pressure, CVP, heart rate and urine output 
remained stable in both groups; HES increased 
cardiac index and several oxygenation parameters 
and decreased APACHE II score
ANP, atrial natriuretic peptide; APACHE, Acute Physiology and Chronic Health Evaluation; aPTT, activated partial thromboplastin time; CVP, 
central venous pressure; DO2I, oxygen delivery index; HES, hydroxyethyl starch; MAP, mean arterial pressure; PaO2/FiO2, ratio of partial pressure 
of arterial oxygen to fraction of inspired oxygen; PCWP, pulmonary capillary wedge pressure; pHi, gastric intramucosal pH; PT, prothrombin time; 
RVEF, right ventricular ejection fraction; sELAM-1, soluble endothelial leukocyte adhesion molecule-1; sICAM-1, soluble intercellular adhesion 
molecule-1; SVRI, systemic vascular resistance index; VO2I, oxygen consumption index.Critical Care    Vol 12 No 2    Jacob et al.
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Table 3
Randomized clinical trials of hyperoncotic albumin in other indications
Trial n Indication Regimen Results
Liver disease
Gentilini et al., 1999 [51] 126 Cirrhosis and refractory 
ascites
Inpatient treatment with 
12.5 g/day 25% albumin 
plus diuretics vs diuretics 
alone
90.5% cumulative treatment response rate in 
group receiving albumin vs 74.7% in control 
group (p < 0.05); shorter hospital stay (p < 
0.05) in group receiving albumin (20 vs 24 
days) resulting in 59% cost savings; no 
survival difference
Sort et al., 1999 [53] 126 Cirrhosis with ascites and 
spontaneous bacterial 
peritonitis
1.5 g/kg 20% albumin 
within 6 h of diagnosis and 
1 g/kg on day 3 vs no 
albumin; intravenous 
cefotaxime in both groups
Renal impairment in 33% of control group vs 
10% of albumin recipients (p = 0.002); 29% 
hospital mortality in control group vs 10% of 
group receiving albumin (p = 0.01); 41% and 
22% mortality, respectively, by 3 months of 
follow-up (p = 0.03)
Fernández et al., 2005 [58] 20 Cirrhosis and spontaneous 
bacterial peritonitis
20% albumin vs 6% HES 
200/0.5, both 
administered at 1.5 g/kg 
after baseline 
measurements and 1.0 g/
kg on day 3
Albumin increased mean arterial pressure and 
decreased plasma renin activity; no 
improvements in circulatory function in 
patients receiving HES; 4 of 10 HES 
recipients developed spontaneous bacterial 
peritonitis-induced circulatory dysfunction or 
renal failure, whereas neither complication 
occurred in any of the 10 patients receiving 
albumin
High-risk neonates
McMurray et al., 1948 [35] 33 Premature infants with low 
birth weight
3 ml 25 g/dl albumin 
injected per pound body 
weight 1–2 times weekly 
vs no albumin
8.5 days shorter mean time to regain birth 
weight in infants receiving albumin (p = 0.02) 
and significantly fewer illnesses
Greenough et al., 1993 [42] 30 Ventilator-dependent ill 
pre-term infants
5 ml/kg 20% albumin vs 
placebo
Albumin reduced edema based on weight 
loss (p < 0.01), whereas control group 
gained weight (p < 0.05); 27% reduction in 
inspired oxygen requirement after albumin 
treatment (p < 0.05) with no change in 
control group
Gürkan et al., 2001 [56] 18 Newborns with asphyxia 
and brain edema
0.5 g/kg 20% albumin vs 
routine fluid
Higher modified Apgar score in group 
receiving albumin after 24 h (p < 0.001) with 
difference persisting 8 days; cerebral edema 
reduced in greater proportion of albumin than 
control group as judged by head ultrasound; 
28% shorter hospital stay in albumin-treated 
group (p < 0.01)
Brain injury
Goslinga et al., 1992 [40] 300 Acute ischemic stroke Normovolemic 
hemodilution with 20% 
albumin vs crystalloids
In subgroup with normal hematocrit 
accounting for two-thirds of study population, 
mortality and disability at 3 months 
significantly lower among albumin recipients
Tomita et al., 1994 [43] 18 Closed head injury High-oncotic-pressure 
therapy with 25% albumin 
and furosemide vs normal-
oncotic-pressure therapy
Recovery with minimal or no neurological 
deficit in patients of high-oncotic-pressure 
therapy group; persistent vegetative state or 
death in 30% of patients receiving normal-
oncotic-pressure therapy
Intradialytic hypotension
van der Sande et al., 1999 [54] 10 Crossover trial of stable 
dialysis patients
20% albumin vs 10% HES 
200/0.5 vs saline, in 
conjunction with 
ultrafiltration and 
hemodialysis
Greater decrease in blood volume with saline 
than other fluids (p < 0.05)
van der Sande et al., 2000 [55] 9 Crossover trial of cardiac-
compromised dialysis 
patients
100 ml of 20% albumin vs 
10% HES 200/0.5 vs 3% 
hypertonic saline, in 
conjunction with 
ultrafiltration and 
hemodialysis
Greater intradialytic reductions in systolic 
blood pressure (p < 0.05) and blood volume 
(p < 0.05) with hypertonic saline than either 
albumin or HESAvailable online http://ccforum.com/content/12/2/R34
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Nephrotic syndrome
Hyperoncotic albumin was investigated in three randomized
trials of nephrotic syndrome (Table 3). Hyperoncotic albumin
with concomitant furosemide accelerated diuresis and pro-
moted body weight loss [38]. In addition, hyperoncotic albu-
min potentiated both the diuretic and natriuretic effects of
furosemide [50,57].
Survival
Mortality data were available for 24 randomized comparisons.
The median duration of follow-up was 5 days (IQR, 5 to 13
days). Three trials [40,51,53] were specifically designed to
assess survival as a primary study endpoint. No patient died in
4 of the 24 comparisons [37,39,41,56]. The remaining 20
comparisons with at least one death were included in a quan-
titative meta-analysis of survival (Figure 2). Total mortality in
the 20 comparisons (Figure 2) was 266/1,287 (21%). In the
meta-analysis, there was no evidence of either heterogeneity
(p = 0.86) or publication bias (p = 0.87). The observed statis-
tical power of the meta-analysis was 98% to detect a 35%
reduction in relative mortality risk by hyperoncotic albumin (RR
0.65) and 82% to demonstrate a 35% relative mortality risk
increase (RR 1.35). No significant overall effect of hyperon-
cotic albumin on survival was detected (RR 0.95; CI 0.78 to
1.17).
Discussion
This is the first systematic review exclusively focused on hyper-
oncotic albumin. With this focus, variability due to potential dif-
ferences in the effects of 4 to 5% vs 20 to 25% albumin is
eliminated.
The included randomized clinical trials supplied evidence of
clinical benefits such as reduction in morbidity in high-risk
neonates [35] and brain injury [40], avoidance of major organ
edema in surgery [39] and high-risk neonates [56] and preser-
vation of renal function in surgery [41] and liver disease [53].
These benefits in the randomized trials are consistent with
extensive evidence from non-randomized clinical investiga-
tions, as discussed below.
Limitations
The included randomized trials addressed diverse clinical indi-
cations for hyperoncotic albumin, and the number of trials
focusing on any single indication was, in most instances,
relatively small. Within any particular indication, furthermore,
no more than two trials evaluated clinically relevant endpoints
of the same type. Consequently, firm conclusions about clini-
cal benefit in defined indications are difficult to draw. Another
limitation was the variety of control regimens. Treatment
effects of hyperoncotic albumin might differ, for instance, in
comparison to crystalloid vs colloid control fluid.
The available data in the categories of trauma and of sepsis
were predominantly furnished by a single group of
investigators, and 10 of the 11 randomized comparisons from
this group were performed using the same trial design (Tables
1 and 2). The generalizability of those results is uncertain, and
further trials are needed in those categories.
In the survival meta-analysis, the short median follow-up of 5
days may account partly or entirely for the lack of overall effect.
Follow-up of 30 days or longer is typical for outcomes trials.
Even at 30 days survival, differences may be substantially
underestimated compared with those observed at 90 days
[60]. In all three included trials designed to assess survival, the
follow-up period was at least 90 days [40,51,53].
As in previous systematic reviews of albumin administration
[26,27], one of the control regimens represented among the
trials in this review was no albumin, accounting for six of the
included trials (24%). No albumin as the designated control
regimen did not necessarily mean no volume expansion, how-
ever. In one surgery trial [36] the no-albumin control group
received a cumulative mean volume of 24 l non-colloid fluids
over the course of the 5-day study. In two trials of high-risk
Nephrotic syndrome
Kosnadi et al., 1987 [38] 24 Children with nephrotic 
syndrome
20% albumin + furosemide 
+ prednisone vs human 
plasma + furosemide + 
prednisone vs prednisone 
alone
Diuresis earlier with albumin + furosemide + 
prednisone vs prednisone alone (p = 0.011) 
and percent body weight loss greater (p < 
0.01)
Fliser et al., 1999 [50] 9 Double-blind, placebo-
controlled crossover trial in 
patients with nephrotic 
syndrome on standardized 
salt intake
200 ml 20% albumin + 
0.9% NaCl sham infusion 
vs 200 ml 20% albumin + 
60 mg furosemide vs 60 
mg furosemide + sham 
infusion of 200 ml H2O
Urinary volume and sodium excretion higher 
by 20% (p < 0.05 and p < 0.01, respectively) 
during first 8 h with albumin + furosemide 
than furosemide alone
Na et al., 2001 [57] 7 Crossover trial in patients 
with nephrotic syndrome
100 ml 20% albumin vs 
5% dextrose followed by 
160 mg of furosemide
Albumin potentiated the diuretic effect of 
furosemide
HES, hydroxyethyl starch.
Table 3 (Continued)
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neonates, the no albumin control regimen consisted of routine
fluid [56] or 5 ml/kg infant maintenance fluid [42]. No albumin
control group volume expansion, if any, in three other trials was
unspecified [35,51,53]. If control patients in any of those three
trials did not receive volume expanders, then observed differ-
ences between the hyperoncotic albumin and control arms
might have reflected volume expansion rather than a specific
effect of hyperoncotic albumin per se. In that scenario, it is
possible that an alternative fluid could exert effects similar to
those observed with hyperoncotic albumin.
These limitations highlight the need for further trials. There is
consistent evidence that hyperoncotic albumin has the capac-
ity to reduce edema; however, the impact of edema reduction
on outcomes requires further investigation. Short follow-up
has been a deficiency of most hyperoncotic albumin trials to
date, and future trials with longer follow-up are essential to
assess outcomes. Especially in the areas of surgery, trauma
and sepsis existing data need to be supplemented by addi-
tional trials. Lastly, standardized and well-specified control
regimens will be important in future trials so that clearer infer-
ences can be drawn concerning the specific effects of hyper-
oncotic albumin vs those of particular alternative fluids or
generic volume expansion.
Small-volume resuscitation
A small volume can be administered more rapidly, and so the
period during which the patient remains at increased risk of
Figure 2
Quantitative meta-analysis of survival in hyperoncotic albumin compared with control group Quantitative meta-analysis of survival in hyperoncotic albumin compared with control group. Data points are scaled in proportion to meta-analytic 
weight. CI, 95% confidence interval; RR, relative risk.Available online http://ccforum.com/content/12/2/R34
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poor outcome can be commensurately reduced. In the pre-
hospital setting, hyperoncotic albumin could accelerate hemo-
dynamic stabilization and transport to hospital. Another advan-
tage in the pre-hospital setting is the portability of small
hyperoncotic albumin volumes.
In surgical patients, small-volume hyperoncotic albumin resus-
citation may simplify fluid management by maintaining a stable
hemodynamic state. In a retrospective study of 28 patients
undergoing pelvic exenterations for gynecological malignan-
cies, recipients of 25% albumin required fewer boluses of fluid
(p < 0.01), electrolyte (p < 0.01) and diuretic (p < 0.01) and
could be started sooner on central hyperalimentation (p <
0.05) than the group receiving crystalloid [61].
Speed of resuscitation may also be of the essence in rapidly
progressing conditions such as spontaneous bacterial perito-
nitis [53] and in the urgent care of high-risk neonates [20]. In
pre-term infants with respiratory distress syndrome, intrave-
nous administration of 1 g/kg 25% albumin over a 10 min
period increased blood volume (p < 0.0005) and mean arterial
blood pressure (p < 0.05) within 10 min after infusion was
completed [20]. Albumin also significantly augmented glomer-
ular filtration in that study, as indicated by increased creatinine
clearance (p < 0.005).
Edema
Formation of edema serves as a harbinger of organ failure [62]
and may, depending upon the tissues affected, lead to impair-
ments in gas exchange, myocardial compliance, neurocogni-
tive function, gut barrier competence, nutrient absorption and
wound healing. Pulmonary edema, for instance, is associated
with prolonged ventilator dependence and intensive care unit
stay [63]. Furthermore, positive fluid balance appears to be
predictive of poorer survival in sepsis [64]. Encephalopathy
may occur at least as frequently as other forms of organ dam-
age during sepsis [65]. Contributors to septic encephalopathy
are reduced cerebral blood flow and oxygen extraction by the
brain and cerebral edema [65]. While edema may be ade-
quately tolerated by many patients, such as young serious
trauma victims, more grave consequences may be faced by
elderly or frail patients in whom edema may retard oxygen
delivery to the lungs, myocardium and brain.
The impact of cerebral edema on outcome after subarachnoid
hemorrhage (SAH) was investigated in 374 patients [66]. In a
multivariate analysis assessing 16 significant univariate pre-
dictors, cerebral edema demonstrated by computed tomogra-
phy was an independent risk factor both for death (odds ratio
2.5; CI 1.1 to 5.6) and for either death or severe disability
(odds ratio 2.5; CI 1.2 to 5.4). Severe disability was defined as
a modified Rankin scale score of > 3. These observations
support a causal role for cerebral edema in producing poor
outcomes and prompted the investigators to conclude: 'Criti-
cal care management strategies that minimize edema forma-
tion after SAH may improve outcome' [66]. Similarly, in a
prospective study of 113 non-traumatic SAH patients evalu-
ated by comprehensive neuropsychological testing at 3
months, cerebral edema was an independent risk factor for
cognitive impairment [67].
Hyperoncotic albumin may be of particular clinical value in
edematous states such as those encountered in liver disease,
high-risk neonates, brain injury and nephrotic syndrome (Table
3). While edema may pose problems in sepsis as well, this
review suggested advantages of HES over albumin in sepsis,
e.g., higher cardiac index and oxygenation. However, follow-up
in all the included sepsis trials was only 5 days. With follow-up
of 30 days or longer HES has been shown in randomized trials
to increase the incidence of acute renal failure among patients
with severe sepsis or septic shock [60,68]. Hyperoncotic
albumin displays protective effects on the kidney [41,53] and
hence would likely offer a safer fluid management alternative
than HES in sepsis.
The randomized trial evidence showing the capacity of hyper-
oncotic albumin to reduce edema is supplemented by non-ran-
domized clinical studies and animal models in the areas of
high-risk neonates, brain injury and nephrotic syndrome.
Among 10 normotensive premature infants with idiopathic res-
piratory distress syndrome, 20% albumin reduced body
weight (p < 0.01), indicating lessened edema, and improved
urine output (p < 0.05) within 6 h [69].
Decreased cerebral edema after hyperoncotic albumin admin-
istration was shown in one included randomized trial [56].
Reduction in cerebral edema and other sequelae of brain injury
by hyperoncotic albumin has also been repeatedly
demonstrated in other studies. In a non-randomized trial of 22
patients with putaminal hemorrhage, 50 to 100 ml/day of 25%
albumin with concomitant furosemide significantly reduced
brain edema as assessed by computed tomography [70]. No
albumin recipient died or remained in a vegetative state com-
pared with 27% of crystalloid recipients. In a cohort study of
10 patients with elevated intracranial pressure and brain
edema, infusion of 2 g/kg 25% albumin over 60 min produced
a significant and long-lasting (≥ 9 h) decline in intracerebral
pressure [71]. Among hemorrhagic stroke patients, rapid infu-
sion of 50 ml 20% albumin promptly and significantly reversed
electroencephalographic abnormalities [72]. The randomized,
double-blinded, placebo-controlled multi-center Albumin in
Acute Stroke (ALIAS) clinical trial funded by the US National
Institutes with a target enrollment of 1,800 patients is evaluat-
ing the neuroprotective effects of 25% albumin as compared
with saline [73].
According to experimental cerebral ischemia studies, hyperon-
cotic albumin can reduce infarct volume and edema, augment
cortical perfusion and improve functional outcome [74,75]. In
head trauma models, hyperoncotic albumin increased neuro-Critical Care    Vol 12 No 2    Jacob et al.
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logical score and reduced brain tissue edema and damage
[76-78].
All three included randomized trials in nephrotic syndrome
[38,50,57] indicated the ability of hyperoncotic to promote
diuresis, and one of these trials [38] also provided direct evi-
dence of edema reduction. In a non-randomized study of 14
severely edematous children with minimal change nephrotic
syndrome, 20% albumin infused at an albumin dose of 0.5 g/
kg over 1 h followed by furosemide reduced pretibial edema
and body weight within 1 h (p < 0.05) [79]. These effects per-
sisted for at least 24 h (p < 0.005).
Anti-inflammatory activity
Starling forces may be sufficient to explain the effectiveness of
hyperoncotic albumin for small-volume resuscitation and
edema reduction. However, additional mechanisms such as
anti-inflammatory and antioxidant activity may contribute to the
clinical benefits of hyperoncotic albumin. Furthermore, at least
some of these mechanisms are specific to hyperoncotic rather
than 4 to 5% albumin. Thus, in an in vitro study of blood spec-
imens from 10 healthy adult human volunteers, dilution with
HES 450/0.7 produced a dose-dependent increase in neu-
trophil activation to 19-fold the baseline level [80]. The
increase after dilution with various crystalloids was to 13- to
19-fold the baseline level and with 5% albumin twofold. In con-
trast, there was no evidence of neutrophil activation by 25%
albumin.
Antioxidant effects
The reduced thiol moiety on cysteine 34 of albumin can play a
direct antioxidant role. In a randomized clinical trial of 20
patients with acute lung injury due to trauma, pneumonia, sep-
sis and other insults, repeated administration of 25% albumin
elevated plasma thiol concentration (p = 0.0001) and total
antioxidant capacity (p = 0.033) compared with saline pla-
cebo [81].
Safety
The capacity of hyperoncotic albumin to shift fluid from the
interstitium to the intravascular space may be viewed as a two-
edged sword, depending upon the hydration state of the
patient. In edematous states, such fluid shifts may be
desirable. Conversely, hyperoncotic albumin should probably
be avoided in patients with severe dehydration [3].
High doses of hyperoncotic albumin could potentially increase
pulmonary edema and capillary leak. In one widely cited rand-
omized trial of Lucas et al. [82], patients receiving very high
hyperoncotic albumin doses (1,142 g) and total fluid volumes
(44.9 l) displayed impairment in pulmonary function.
Commentators have ascribed that result to fluid overload
rather than hyperoncotic albumin per se, however [83,84]. The
trial of Lucas et al. was not included in the present review
because albumin was administered with the aim of elevating
serum albumin concentration rather than expanding intravas-
cular volume, and indeed the attained central venous pressure
(mean 18.6 cm H2O) was supranormal.
In a dose-escalation study of 25% albumin treatment in 82
patients with acute ischemic stroke, mild or moderate pulmo-
nary edema was observed in 13% of the patients [85]. This
adverse effect was readily managed with diuretics, and 25%
albumin doses up to 2 g/kg could be tolerated without major
dose-limiting complications.
None of the trials included in the present review or in a prior
systematic review of both hyperoncotic and 4 to 5% albumin
[28] has indicated harmful effects attributable to albumin. A
Cochrane meta-analysis encompassing both 4 to 5% and 20
to 25% solutions suggested increased mortality among albu-
min recipients (RR 1.7) [26]. That finding could not be repli-
cated either in the SAFE trial [25] or a more comprehensive
subsequent meta-analysis [27]. In the present survival meta-
analysis, which was adequately powered to detect a relative
mortality risk increase only half as great as that reported by the
Cochrane investigators, there was no evidence of poorer sur-
vival among hyperoncotic albumin recipients.
Conclusion
Small-volume resuscitation with hyperoncotic albumin can
speed the stabilization of the patient and alleviate potentially
harmful edema. Nevertheless, the clinical benefits of hyperon-
cotic albumin remain incompletely characterized. Further trials
are needed, especially in the areas of surgery, trauma and
sepsis.
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